We found that the predicted risk groups using SHP as a single gene classifier were significantly associated with survival outcome for patients with stage I lung cancer in the Consortium samples (Figure 5A; p = 0.033), whereas the PR signature was marginally predictive (Figure 5B; p = 0.069). This evidence concerns the gene NR0B2 and lung carcinoma.